Antitumor mechanisms of Z-10O, an immunomodulatory arabinomannan extracted from mycobacterium tuberculosis: The importance of lymphocytes infiltrated into tumor sites

H. Sasaki, D. Scmitt, Y. Hayashi, R. B. Pollard, Fujio Suzuki

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The mechanisms of increased host resistance to tumors following treatment with Z-100, an arabinomannan extracted from mycobacterium tuberculosis, were investigated in mice bearing syngeneic solid tumors. When BALB/c mice bearing Meth-A solid tumors were treated intralesionally (i.l.) with a 10 mg/kg dose of Z100, 74% of tumor growth was inhibited in the test group as compared with control mice treated with saline. However, no significant tumor inhibitory activity was observed when these mice were treated with various doses of Z-100 i.p. or i.v. In addition, tumor growth in X-irradiated mice (450 R, whole-body irradiation) and in mice treated with antilymphocyte serum was not suppressed even though Z-100 was administered into the tumor. The number oflymphocytes isolated from Z100-treated tumor tissues increased 3.2-fold (14 days after the tumor inoculation), whereas no change in the number of tumor-infiltrating lymphocytes was demonstrated in mice treated with Z100 i.p. or i.v. as compared to controls. When BALB/c mice were inoculated s.c. with a mixture of Meth-A tumor cells (1 X 106 cells) and lymphocytes (2 X 105s cells) derived from Z1OO-treated tumor tissues in a Winn's neutralization test, decreased growth of solid tumors was demonstrated as compared with that of control mice inoculated with tumor cells alone. However, no such inhibition of tumor growth was observed in mice inoculated with a mixture of the tumor cells and lymphocytes obtained from tumor tissues of control mice at the same effector to target cell ratio. These results suggest that the antitumor activity of Z-100 administered i.l. against Meth-A solid tumors in BALB/c mice might be displayed through the activity of lymphocytes infiltrated into tumor tissues.

Original languageEnglish (US)
Pages (from-to)104-112
Number of pages9
JournalNatural Immunity
Volume12
Issue number2
StatePublished - 1993

Fingerprint

Mycobacterium tuberculosis
Lymphocytes
Neoplasms
arabinomannan
Growth
Tumor-Infiltrating Lymphocytes
Neutralization Tests
Antilymphocyte Serum
Whole-Body Irradiation

Keywords

  • Antitumor activity
  • Intralesional administration
  • natural immunomodulator
  • Tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Immunology

Cite this

Antitumor mechanisms of Z-10O, an immunomodulatory arabinomannan extracted from mycobacterium tuberculosis : The importance of lymphocytes infiltrated into tumor sites. / Sasaki, H.; Scmitt, D.; Hayashi, Y.; Pollard, R. B.; Suzuki, Fujio.

In: Natural Immunity, Vol. 12, No. 2, 1993, p. 104-112.

Research output: Contribution to journalArticle

@article{8c46bc06600744978c19fa9d0c8774fa,
title = "Antitumor mechanisms of Z-10O, an immunomodulatory arabinomannan extracted from mycobacterium tuberculosis: The importance of lymphocytes infiltrated into tumor sites",
abstract = "The mechanisms of increased host resistance to tumors following treatment with Z-100, an arabinomannan extracted from mycobacterium tuberculosis, were investigated in mice bearing syngeneic solid tumors. When BALB/c mice bearing Meth-A solid tumors were treated intralesionally (i.l.) with a 10 mg/kg dose of Z100, 74{\%} of tumor growth was inhibited in the test group as compared with control mice treated with saline. However, no significant tumor inhibitory activity was observed when these mice were treated with various doses of Z-100 i.p. or i.v. In addition, tumor growth in X-irradiated mice (450 R, whole-body irradiation) and in mice treated with antilymphocyte serum was not suppressed even though Z-100 was administered into the tumor. The number oflymphocytes isolated from Z100-treated tumor tissues increased 3.2-fold (14 days after the tumor inoculation), whereas no change in the number of tumor-infiltrating lymphocytes was demonstrated in mice treated with Z100 i.p. or i.v. as compared to controls. When BALB/c mice were inoculated s.c. with a mixture of Meth-A tumor cells (1 X 106 cells) and lymphocytes (2 X 105s cells) derived from Z1OO-treated tumor tissues in a Winn's neutralization test, decreased growth of solid tumors was demonstrated as compared with that of control mice inoculated with tumor cells alone. However, no such inhibition of tumor growth was observed in mice inoculated with a mixture of the tumor cells and lymphocytes obtained from tumor tissues of control mice at the same effector to target cell ratio. These results suggest that the antitumor activity of Z-100 administered i.l. against Meth-A solid tumors in BALB/c mice might be displayed through the activity of lymphocytes infiltrated into tumor tissues.",
keywords = "Antitumor activity, Intralesional administration, natural immunomodulator, Tumor-infiltrating lymphocytes",
author = "H. Sasaki and D. Scmitt and Y. Hayashi and Pollard, {R. B.} and Fujio Suzuki",
year = "1993",
language = "English (US)",
volume = "12",
pages = "104--112",
journal = "Natural Immunity",
issn = "1018-8916",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Antitumor mechanisms of Z-10O, an immunomodulatory arabinomannan extracted from mycobacterium tuberculosis

T2 - The importance of lymphocytes infiltrated into tumor sites

AU - Sasaki, H.

AU - Scmitt, D.

AU - Hayashi, Y.

AU - Pollard, R. B.

AU - Suzuki, Fujio

PY - 1993

Y1 - 1993

N2 - The mechanisms of increased host resistance to tumors following treatment with Z-100, an arabinomannan extracted from mycobacterium tuberculosis, were investigated in mice bearing syngeneic solid tumors. When BALB/c mice bearing Meth-A solid tumors were treated intralesionally (i.l.) with a 10 mg/kg dose of Z100, 74% of tumor growth was inhibited in the test group as compared with control mice treated with saline. However, no significant tumor inhibitory activity was observed when these mice were treated with various doses of Z-100 i.p. or i.v. In addition, tumor growth in X-irradiated mice (450 R, whole-body irradiation) and in mice treated with antilymphocyte serum was not suppressed even though Z-100 was administered into the tumor. The number oflymphocytes isolated from Z100-treated tumor tissues increased 3.2-fold (14 days after the tumor inoculation), whereas no change in the number of tumor-infiltrating lymphocytes was demonstrated in mice treated with Z100 i.p. or i.v. as compared to controls. When BALB/c mice were inoculated s.c. with a mixture of Meth-A tumor cells (1 X 106 cells) and lymphocytes (2 X 105s cells) derived from Z1OO-treated tumor tissues in a Winn's neutralization test, decreased growth of solid tumors was demonstrated as compared with that of control mice inoculated with tumor cells alone. However, no such inhibition of tumor growth was observed in mice inoculated with a mixture of the tumor cells and lymphocytes obtained from tumor tissues of control mice at the same effector to target cell ratio. These results suggest that the antitumor activity of Z-100 administered i.l. against Meth-A solid tumors in BALB/c mice might be displayed through the activity of lymphocytes infiltrated into tumor tissues.

AB - The mechanisms of increased host resistance to tumors following treatment with Z-100, an arabinomannan extracted from mycobacterium tuberculosis, were investigated in mice bearing syngeneic solid tumors. When BALB/c mice bearing Meth-A solid tumors were treated intralesionally (i.l.) with a 10 mg/kg dose of Z100, 74% of tumor growth was inhibited in the test group as compared with control mice treated with saline. However, no significant tumor inhibitory activity was observed when these mice were treated with various doses of Z-100 i.p. or i.v. In addition, tumor growth in X-irradiated mice (450 R, whole-body irradiation) and in mice treated with antilymphocyte serum was not suppressed even though Z-100 was administered into the tumor. The number oflymphocytes isolated from Z100-treated tumor tissues increased 3.2-fold (14 days after the tumor inoculation), whereas no change in the number of tumor-infiltrating lymphocytes was demonstrated in mice treated with Z100 i.p. or i.v. as compared to controls. When BALB/c mice were inoculated s.c. with a mixture of Meth-A tumor cells (1 X 106 cells) and lymphocytes (2 X 105s cells) derived from Z1OO-treated tumor tissues in a Winn's neutralization test, decreased growth of solid tumors was demonstrated as compared with that of control mice inoculated with tumor cells alone. However, no such inhibition of tumor growth was observed in mice inoculated with a mixture of the tumor cells and lymphocytes obtained from tumor tissues of control mice at the same effector to target cell ratio. These results suggest that the antitumor activity of Z-100 administered i.l. against Meth-A solid tumors in BALB/c mice might be displayed through the activity of lymphocytes infiltrated into tumor tissues.

KW - Antitumor activity

KW - Intralesional administration

KW - natural immunomodulator

KW - Tumor-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=0027287937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027287937&partnerID=8YFLogxK

M3 - Article

C2 - 8318815

AN - SCOPUS:0027287937

VL - 12

SP - 104

EP - 112

JO - Natural Immunity

JF - Natural Immunity

SN - 1018-8916

IS - 2

ER -